Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/18/2013

Company Name Symbol %Change
STAAR SURGIC STAA
10.98%
LUMOS NETWOR LMOS
5.70%
INSTEEL IND IIIN
5.28%
ERICKSON AIR EAC
5.10%
ASSURED GUAR AGO
4.98%

CLX Downgraded to Neutral

by Zacks Equity Research

November 13, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, we have downgraded our long-term ‘Neutral’ recommendation on California-based The Clorox Company (CLX - Analyst Report). Our recommendation is based on the company’s declining volume, uncertainty in Venezuela and the tough macro-economic situation.

Clorox recently reported its first quarter 2013 results. In the quarter, the company’s total volume edged down 1% primarily due to increased pricing resulting from passing of higher input costs to consumers. Further, we believe that any further rise in raw material prices will lead to increased pricing of Clorox’s products, which may adversely affect its volume, and henceforth the total sales.

Moreover, Clorox has a substantial exposure in Venezuela, due to which it may face difficulties in maintaining its profitability if the Venezuelan government restricts pricing decision of the companies to offset the possible rise in raw material prices.

Another negative point for the company is its highly leveraged balance sheet with long-term debt of $1,571 million and debt-to-capitalization ratio of over 109%, recorded at the end of fiscal 2012. The high debt level may adversely affect the company’s financial flexibility as well as its ability to pursue acquisitions or expand operations organically.

On the other side, we are impressed with Clorox’s cost-saving initiatives, which helped earnings in first-quarter 2013 to increase by 3% to $1.01 per share, beating the Zacks Consensus Estimate of 95 cents. Net sales elevated 2.5% year over year primarily due to increased pricing, offset in part by lower volumes and unfavorable foreign exchange.

Further, the company confirmed its fiscal 2013 earnings guidance between $4.20 and $4.35 per share. Moreover, we expect the company’s charcoal and bleach sales to improve in second-quarter due to the damage caused by hurricane Sandy in the East Coast region.

Moreover, Clorox's diversified brand portfolio positions it well above its peers to generate above-average industry growth and sustain itself in the current challenging environment. Going forward, Clorox has decided to tap the opportunities available in Middle East and other growing Asian countries. We believe that with less competitiveness and penetration along with healthy population and rising household income, these countries will provide huge growth potential for the company.

Considering these above factors, it can be stated that the investors should wait to own this stock until its strategic initiatives reflect better visibility.

One of the company’s peers Colgate-Palmolive Co. (CL - Analyst Report) also carries a long-term ‘Neutral’ recommendation on the stock.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.